المؤلفون: Shah, R. J., Wickersham, N., Lederer, D. J., Palmer, S. M., Cantu, E., Diamond, J. M., Kawut, S. M., Lama, V. N., Bhorade, S., Crespo, M., Demissie, E., Sonett, J., Wille, K., Orens, J., Weinacker, A., Shah, P., Arcasoy, S., Wilkes, D. S., Christie, J. D., Ware, L. B.

مصطلحات موضوعية: Lung Transplantation, Primary Graft Dysfunction, CC‐16, Acute Lung Injury, Biomarkers, Medicine (General), Health Sciences

وصف الملف: application/pdf

العلاقة: Shah, R. J.; Wickersham, N.; Lederer, D. J.; Palmer, S. M.; Cantu, E.; Diamond, J. M.; Kawut, S. M.; Lama, V. N.; Bhorade, S.; Crespo, M.; Demissie, E.; Sonett, J.; Wille, K.; Orens, J.; Weinacker, A.; Shah, P.; Arcasoy, S.; Wilkes, D. S.; Christie, J. D.; Ware, L. B. (2014). "Preoperative Plasma Club (Clara) Cell Secretory Protein Levels Are Associated With Primary Graft Dysfunction After Lung Transplantation." American Journal of Transplantation 14(2): 446-452.; https://hdl.handle.net/2027.42/102697Test; American Journal of Transplantation; Christie JD, Kotloff RM, Ahya VN, et al. The effect of primary graft dysfunction on survival after lung transplantation. Am J Respir Crit Care Med 2005; 171: 1312 – 1316.; Christie JD, Bavaria JE, Palevsky HI, et al. Primary graft failure following lung transplantation. Chest 1998; 114: 51 – 60.; Covarrubias M, Ware LB, Kawut SM, et al. Plasma intercellular adhesion molecule‐1 and von Willebrand factor in primary graft dysfunction after lung transplantation. Am J Transplant 2007; 7: 2573 – 2578.; Christie JD, Kotloff RM, Pochettino A, et al. Clinical risk factors for primary graft failure following lung transplantation. Chest 2003; 124: 1232 – 1241.; Christie JD, Carby M, Bag R, et al. Report of the ISHLT Working Group on Primary Lung Graft Dysfunction Part II: Definition. A consensus statement of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 2005; 24: 1454 – 1459.; Panwar R, Venkatesh B, Kruger P, et al. Plasma protein C levels in immunocompromised septic patients are significantly lower than immunocompetent septic patients: A prospective cohort study. J Hematol Oncol 2009; 2: 43.; Jorens PG, Sibille Y, Goulding NJ, et al. Potential role of Clara cell protein, an endogenous phospholipase A2 inhibitor, in acute lung injury. Eur Respir J 1995; 8: 1647 – 1653.; Seam N, Meduri GU, Wang H, et al. Effects of methylprednisolone infusion on markers of inflammation, coagulation, and angiogenesis in early acute respiratory distress syndrome. Crit Care Med 2012; 40: 495 – 501.; Pires‐Neto RC, Morales MMB, Lancas T, et al. Expression of acute‐phase cytokines, surfactant proteins, and epithelial apoptosis in small airways of human acute respiratory distress syndrome. J Crit Care 2013; 28: 111.e9 – 111.e15.; Thomsen M, Ingebrigtsen TS, Marott JL, et al. Inflammatory biomarkers and exacerbations in chronic obstructive pulmonary disease. J Am Med Assoc 2013; 309: 2353 – 2361.; Sims MW, Beers MF, Ahya VN, et al. Effect of single vs bilateral lung transplantation on plasma surfactant protein D levels in idiopathic pulmonary fibrosis. Chest 2011; 140: 489 – 496.; Kropski JA, Fremont RD, Calfee CS, Ware LB. Clara cell protein (CC16), a marker of lung epithelial injury, is decreased in plasma and pulmonary edema fluid from patients with acute lung injury. Chest 2009; 135: 1440 – 1447.; Lesur O, Langevin S, Berthiaume Y, et al. Outcome value of Clara cell protein in serum of patients with acute respiratory distress syndrome. Intensive Care Med 2006; 32: 1167 – 1174.; Janssen R, Sato H, Grutters JC, et al. Study of Clara cell 16, KL‐6, and surfactant protein‐D in serum as disease markers in pulmonary sarcoidosis. Chest 2003; 124: 2119 – 2125.; Broeckaert F, Clippe A, Knoops B, Hermans C, Bernard A. Clara cell secretory protein (CC16): Features as a peripheral lung biomarker. Ann N Y Acad Sci 2000; 923: 68 – 77.; Sterne JA, White IR, Carlin JB, et al. Multiple imputation for missing data in epidemiological and clinical research: Potential and pitfalls. BMJ 2009; 338: 157 – 160.; Shah RJ, Diamond JM, Cantu E, et al. Use of a simple prediction model improves pre‐transplant risk stratification for primary graft dysfunction after lung transplantation. Am J Respir Crit Care Med 2013; 187: A3773.; Maldonado G, Greenland S. Simulation study of confounder‐selection strategies. Am J Epidemiol 1993; 138: 923 – 936.; Lederer DJ, Kawut SM, Wickersham N, et al. Obesity and primary graft dysfunction after lung transplantation: The Lung Transplant Outcomes Group Obesity Study. Am J Respir Crit Care Med 2011; 184: 1055 – 1061.; Royston P, Ambler G, Sauerbrei W. The use of fractional polynomials to model continuous risk variables in epidemiology. Int J Epidemiol 1999; 28: 964 – 974.; Hermans C, Petrek M, Kolek V, et al. Serum Clara cell protein (CC16), a marker of the integrity of the air‐blood barrier in sarcoidosis. Eur Respir J 2001; 18: 507 – 514.; Hoffman SA, Wang L, Shah CV, et al. Plasma cytokines and chemokines in primary graft dysfunction post‐lung transplantation. Am J Transplant 2009; 9: 389 – 396.; Lee JC, Christie JD. Primary graft dysfunction. Proc Am Thorac Soc 2009; 6: 39 – 46.; Cypel M, Yeung JC, Liu M, et al. Normothermic ex vivo lung perfusion in clinical lung transplantation. N Engl J Med 2011; 364: 1431 – 1440.; Department of Health and Human Services HRaSA, Healthcare Systems Bureau, Division of Transplantation, Rockville, MD; United Network for Organ Sharing, Richmond, VA. 2012. Annual Report of the U.S. Organ Procurement and Transplantation Network and the Scientific Registry of Transplant Recipients. Transplant Data 1994–2012. 2012.; Diamond JM, Lee JC, Kawut SM, et al. Clinical risk factors for primary graft dysfunction after lung transplantation. Am J Respir Crit Care Med 2013; 187: 527 – 534.; Shah RJ, Bellamy SL, Localio AR, et al. A panel of lung injury biomarkers enhances the definition of primary graft dysfunction (PGD) after lung transplantation. J Heart Lung Transplant 2012; 31: 942 – 949.; Diamond JM, Kawut SM, Lederer DJ, et al. Elevated plasma Clara cell secretory protein concentration is associated with high‐grade primary graft dysfunction. Am J Transplant 2011; 11: 561 – 567.; Christie JD, Shah CV, Kawut SM, et al. Plasma levels of receptor for advanced glycation end products, blood transfusion, and risk of primary graft dysfunction. Am J Respir Crit Care Med 2009; 180: 1010 – 1015.; Christie JD, Robinson N, Ware LB, et al. Association of protein C and type 1 plasminogen activator inhibitor with primary graft dysfunction. Am J Respir Crit Care Med 2007; 175: 69 – 74.

الإتاحة: https://doi.org/10.1111/ajt.12541Test
https://hdl.handle.net/2027.42/102697Test

المؤلفون: Ramphal, K.¹, Cantu, E.¹, Porteous, M.¹, Oyster, M.¹, Kawut, S.¹, Lederer, D.J.², Shah, R.³, Arcasoy, S.², Snyder, L.⁴, Hartwig, M.⁴, Palmer, S.⁴, Wille, K.M.⁵, Ware, L.⁶, Shah, P.⁷, Crespo, M.⁸, Hage, C.⁹, Weinacker, A.¹⁰, Lama, V.¹¹, Suzuki, Y.¹, Orens, J.⁷

المصدر: Journal of Heart & Lung Transplantation. Apr2016 Supplement, Vol. 35, pS314-S315. 1p.

مصطلحات موضوعية: *GRAFT rejection, *CD14 antigen, *LIPOPOLYSACCHARIDES, *CARRIER proteins, *LUNG transplantation, *BIOMARKERS, *DIAGNOSIS